MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Boston Scientific Corp.

Открыт

СекторЗдравоохранение

101.17 0.7

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

100.42

Макс.

101.95

Ключевые показатели

By Trading Economics

Доход

-138M

562M

Продажи

352M

4.6B

P/E

Средняя по отрасли

74.864

57.333

Прибыль на акцию

0.7

Рентабельность продаж

12.322

Сотрудники

53,000

EBITDA

-41M

1B

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+18.99% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

23 июл. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-14B

138B

Предыдущая цена открытия

100.47

Предыдущая цена закрытия

101.17

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Boston Scientific Corp. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 апр. 2025 г., 12:16 UTC

Отчет
Главные движущие силы рынка

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 мар. 2025 г., 12:35 UTC

Приобретения, слияния, поглощения

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 февр. 2025 г., 12:23 UTC

Отчет

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23 апр. 2025 г., 10:32 UTC

Отчет

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 апр. 2025 г., 10:31 UTC

Отчет

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific 1Q EPS 45c >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific 1Q Adj EPS 75c >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific 1Q Sales $4.66B >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 апр. 2025 г., 10:30 UTC

Отчет

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 мар. 2025 г., 11:59 UTC

Приобретения, слияния, поглощения

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 мар. 2025 г., 11:58 UTC

Приобретения, слияния, поглощения

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 мар. 2025 г., 11:58 UTC

Приобретения, слияния, поглощения

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 февр. 2025 г., 21:33 UTC

Отчет

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 февр. 2025 г., 15:20 UTC

Отчет

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 февр. 2025 г., 11:39 UTC

Отчет

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 февр. 2025 г., 11:39 UTC

Отчет

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 февр. 2025 г., 11:38 UTC

Отчет

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 февр. 2025 г., 11:38 UTC

Отчет

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific 4Q Adj EPS 70c >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific 4Q Sales $4.56B >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 февр. 2025 г., 11:37 UTC

Отчет

Boston Scientific 4Q EPS 38c >BSX

Сравнение c конкурентами

Изменение цены

Boston Scientific Corp. Прогноз

Целевая цена

By TipRanks

18.99% рост

Прогноз на 12 месяцев

Средняя 120.35 USD  18.99%

Максимум 135 USD

Минимум 110 USD

Основано на мнении 23 аналитиков Wall Street, спрогнозировавших целевые цены для Boston Scientific Corp. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

23 ratings

22

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

95.25 / 102.37Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.